HomeHealthMore than 2,000 Biopharma Leaders Come Together at Veeva R&D and Quality...

More than 2,000 Biopharma Leaders Come Together at Veeva R&D and Quality Summit to Advance Drug Development

Published on

<br /> More than 2,000 Biopharma Leaders Come Together at Veeva R&D and Quality Summit to Advance Drug Development<br />

More than 2,000 Biopharma Leaders Come Together at Veeva R&D and Quality Summit to Advance Drug Development

PR Newswire


Keynote speakers AbbVie, AstraZeneca, Boehringer Ingelheim, CSL Behring, and GSK headline one of the industry’s largest events for driving collaboration and innovation



PLEASANTON, Calif.


,


Sept. 13, 2022


/PRNewswire/ —

Veeva Systems

(NYSE: VEEV) today announced that visionaries from AbbVie, AstraZeneca, Boehringer Ingelheim, CSL Behring, and GSK will be keynote speakers at the

2022 Veeva R&D and Quality Summit

on Oct.19 and 20 in

Boston

. Speakers will showcase how innovations and advancements in clinical, quality, regulatory, and safety enable greater efficiency and speed across the product lifecycle.

With more than 2,000 industry professionals and over 100 sessions, Veeva R&D and Quality Summit is one of life sciences’ largest and most impactful events. Attendees will learn strategies to establish a clinical data foundation for patient-centric digital trials, transform quality management across the value chain, optimize regulatory operations, and deliver new levels of productivity in safety. Featured keynotes and sessions include:


  • AbbVie

    sharing its vision for transforming safety to improve patient outcomes.


  • AstraZeneca

    highlighting how modern quality management enables tangible value creation.


  • Boehringer Ingelheim

    on enabling digital execution in clinical trials to bring treatments to patients faster.


  • Global Blood Therapeutics

    explaining ways to turn the trial master file (TMF) into a strategic advantage for fast, accurate clinical trials.


  • GSK

    showing how they built a unified development ecosystem across clinical, quality, and regulatory for speed and agility.


  • Forge Biologics

    discussing how digital quality management helps to accelerate processes and build trust with partners.


  • Moderna

    on the benefits of establishing an end-to-end regulatory system for increased agility and visibility.

“Life sciences has made significant progress in streamlining processes and making information sharing easier,” said

Jim Reilly

, vice president, Veeva Development Cloud strategy. “Veeva R&D and Quality Summit will bring the industry back together in person to connect with peers, share learnings, and discuss strategies that can move the industry forward.”

The event is open exclusively to life sciences industry professionals. Register and stay up to date on the agenda and program details at

veeva.com/Summit

.


Additional Information

Register for Veeva R&D and Quality Summit:

veeva.com/Summit/register


Connect with Veeva on LinkedIn:

linkedin.com/company/veeva-systems


Follow @veevasystems on Twitter:

twitter.com/veevasystems


About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit

veeva.com

.


Contact:


Deivis Mercado


Veeva Systems

925-226-8821


[email protected]

Cision
View original content to download multimedia:

https://www.prnewswire.com/news-releases/more-than-2-000-biopharma-leaders-come-together-at-veeva-rd-and-quality-summit-to-advance-drug-development-301622723.html

SOURCE Veeva Systems

rt More than 2,000 Biopharma Leaders Come Together at Veeva R&D and Quality Summit to Advance Drug Development

Featured image: Megapixl © Ipopba

Disclaimer

Latest News

BD, CerTest Biotec Announce US Commercial Launch of Monkeypox Assay

BD, CerTest Biotec Announce US Commercial Launch of...

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

Creative Medical Technology Announces Peer Reviewed Publication of...

Centene Subsidiary Selected to Continue Serving Nebraska’s Medicaid Managed Care Members

Centene Subsidiary Selected to Continue Serving Nebraska's Medicaid...

More like this

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Optimi (CSE:OPTI)(OTCQX:OPTHF)(FRA:8BN) aiming to become the first vertically integrated psychedelics firm to formulate and...

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

The exclusive license allows GSK to commercialize tebipenem HBr in...

iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline

– Positions Company for leadership in AI-powered drug discovery – ...

CVS Health reports progress against goal to reduce suicide attempts among Aetna members 20% by 2025

CVS Health reports progress against goal to reduce...